Robert Iannone
CIK 1737329 · EVP, Global Head of R&D & CMO · last filed 2026-07-13
Robert Iannone is an EVP, Global Head of R&D & CMO who has filed 42 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing, for PLRX, was dated Jul 13, 2026. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $21.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$21.87M
6
42
-$2.80M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PLRX | Director | — | $1.07 | — | $0 | 1 | 2026-07-13 |
| JAZZ | EVP, Global Head of R&D & CMO | 85,107 | $256.92 | $21.87M | -$2.80M | 23 | 2026-07-02 |
| AUTL | Director | — | $1.45 | — | $0 | 1 | 2026-07-01 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | — | $10.15 | — | $0 | 5 | 2024-06-13 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | — | $1.88 | — | $0 | 6 | 2023-05-04 |
| IMMUNOMEDICS INC (IMMU) Delisted | CHIEF MEDICAL OFFICER | — | — | — | $0 | 2 | 2019-03-18 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-13 | PLRX | Grant (A) | — | $0 | EDGAR |
| 2026-07-02 | JAZZ | Tax (F) | −3,764 | -$894.8K | EDGAR |
| 2026-07-01 | AUTL | Grant (A) | — | $0 | EDGAR |
| 2026-03-09 | JAZZ | Tax (F) | −6,209 | -$1.17M | EDGAR |
| 2026-03-02 | JAZZ | Grant (A) | +14,822 | $0 | EDGAR |
| 2026-01-21 | JAZZ | Mixed | +7,559 | -$708.6K | EDGAR |
| 2025-11-19 | JAZZ | Sell (S) | −7,159 | -$1.20M | EDGAR |
| 2025-11-17 | JAZZ | Notice (144) | −7,159 | -$1.20M | EDGAR |
| 2025-03-12 | JAZZ | Sell (S) | −2,403 | -$332.6K | EDGAR |
| 2025-03-10 | JAZZ | Notice (144) | −1,767 | -$256.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.